You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg Wolff-Parkinson-White and Lown-Ganong-levine syndromes. (b) due to dual AV nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Although TAMBOCOR may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. In these patients, particularly in the presence of impaired left ventricular function, TAMBOCOR should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. Use of TAMBOCOR in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. Life threatening ventricular arrhythmias not controlled by other drugs. Intravenous TAMBOCOR is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requirement. All use of the injection should be in hospitals only. TAMBOCOR tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means. Prescribers should also consult the "Warnings" and "Precautions" section of the approved Product Information.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg Wolff-Parkinson-White and Lown-Ganong-levine syndromes. (b) due to dual AV nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Although TAMBOCOR may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. In these patients, particularly in the presence of impaired left ventricular function, TAMBOCOR should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. Use of TAMBOCOR in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. Life threatening ventricular arrhythmias not controlled by other drugs. Intravenous TAMBOCOR is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requirement. All use of the injection should be in hospitals only. TAMBOCOR tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means. Prescribers should also consult the "Warnings" and "Precautions" section of the approved Product Information.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg Wolff-Parkinson-White and Lown-Ganong-levine syndromes. (b) due to dual AV nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Although TAMBOCOR may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. In these patients, particularly in the presence of impaired left ventricular function, TAMBOCOR should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. Use of TAMBOCOR in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. Life threatening ventricular arrhythmias not controlled by other drugs. Intravenous TAMBOCOR is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requirement. All use of the injection should be in hospitals only. TAMBOCOR tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means. Prescribers should also consult the "Warnings" and "Precautions" section of the approved Product Information.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
